The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

“After treatment with enzalutamide, PSA levels decline due to potent androgen receptor blockade and cell death,” Armstrong ...

Image Caption: The role of SOX2 in lineage conversion from CRPC to NEPC. SOX2’s role in treatment resistance is particularly significant. It supports resistance to chemotherapy by inducing a ...

The addition of the AKT inhibitor capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy (ADT) ...

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

Northwestern Medicine scientists have discovered that a specific long non-coding RNA activates oncogenic signaling pathways ...

From his perspective, one of the most persistent misconceptions in prostate cancer care relates to how patients interpret ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL ...

A common diabetes drug may mimic one key effect of exercise in prostate cancer patients. Researchers found metformin boosts an “exercise molecule” linked to appetite and weight control, even in those ...